West Pharma (WST) Misses Q3 EPS by 10c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $350.18 +2.87%
EPS Growth %: +13.0%
Financial Fact:
Net sales: 376.7M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +13.0%
Financial Fact:
Net sales: 376.7M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q3 EPS of $2.03, $0.10 worse than the analyst estimate of $2.13. Revenue for the quarter came in at $686.9 million versus the consensus estimate of $728.11 million.
GUIDANCE:
West Pharma sees FY2022 revenue of $2.83-2.84 billion, versus the consensus of $2.98 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
